Clinical Trials: Country-Specific Clinical Trials

Clinical Trial Insurance and Liability Coverage in the United States

Posted on digi By digi

Sponsors should: (1) assess coverage needs early in trial planning; (2) purchase tailored liability policies; (3) ensure indemnification language in contracts is clear; (4) disclose coverage in informed consent forms; (5) monitor state-specific laws; (6) conduct site audits for compliance; (7) establish claims management procedures; (8) train staff in insurance communication; and (9) maintain ongoing risk reviews throughout the trial lifecycle.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Site Feasibility and Startup Timelines in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) standardize feasibility questionnaires; (2) pre-negotiate contract templates; (3) prioritize central IRBs; (4) implement electronic submission systems; (5) ensure investigator training early; (6) use risk-based site selection; (7) allocate startup specialists within CRO teams; (8) monitor contract cycle times; (9) maintain transparency with sites; and (10) establish contingency plans for underperforming sites.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

CRO Industry Growth and Competitiveness in India

Posted on digi By digi

The growth of CROs in India is governed by a mix of domestic legislation, international guidance, and evolving best practices. Regulatory oversight is provided primarily by the Central Drugs Standard Control Organization (CDSCO), under the New Drugs and Clinical Trials Rules, 2019 (NDCTR). These rules govern the operations of CROs involved in clinical trials, BA/BE studies, and data management.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

GCP Inspections in the EU: EMA vs Member State Approach

Posted on digi By digi

Inspections of decentralized and digitalized trials are evolving. EMA has emphasized validation of remote monitoring tools, GDPR-compliant data access, and transparency in eConsent. Member States focus more on practical execution of remote visits and IMP storage at patient homes. ATMP and rare disease trials receive heightened scrutiny due to their complexity and risk profiles.
Click to read the full article.

Clinical Trials in EU, Country-Specific Clinical Trials

UK Clinical Trial Application Timelines vs EU

Posted on digi By digi

UK and EU trial application timelines differ post-Brexit but remain broadly harmonised with ICH standards. The UK offers a ~60-day approval window via MHRA/HRA, while EU CTR processes can extend beyond 100 days for multi-country trials. Sponsors should prepare robust dossiers, leverage fast-track options, and seek regulatory advice early to minimise delays and align global development plans.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Risk-Based Monitoring in U.S. Clinical Trials: FDA Guidance and Best Practices

Posted on digi By digi

Sponsors should: (1) define RBM strategies in monitoring plans; (2) identify critical data elements during protocol design; (3) validate centralized monitoring tools; (4) maintain audit trails of monitoring decisions; (5) train staff across all levels; (6) document risk assessments; (7) combine centralized and on-site monitoring effectively; (8) engage CROs with RBM expertise; (9) conduct pilot studies before full implementation; and (10) ensure inspection readiness through robust documentation.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials

Role of AIIMS and Apex Hospitals in Clinical Trials

Posted on digi By digi

India’s regulatory framework for clinical trials, governed by the New Drugs and Clinical Trials Rules, 2019 (NDCTR), recognizes the importance of institutional sites like AIIMS and apex government hospitals. These institutions are often pre-qualified by the Central Drugs Standard Control Organization (CDSCO) for their infrastructure, GCP compliance, and track record.
Click to read the full article.

Clinical Trials in India, Country-Specific Clinical Trials

Patient Recruitment Challenges in UK Clinical Studies

Posted on digi By digi

Patient recruitment challenges in UK clinical studies arise from systemic, logistical, and socio-cultural barriers. While NIHR and NHS provide strong infrastructure, sponsors must adopt simplified protocols, digital solutions, and inclusive engagement strategies to achieve recruitment goals. Early regulatory advice and proactive collaboration with NIHR and RECs are key to overcoming recruitment hurdles and delivering trials on time.
Click to read the full article.

Clinical Trials in UK, Country-Specific Clinical Trials

Clinical Supply Chain Logistics in U.S. Clinical Trials

Posted on digi By digi

Sponsors should: (1) validate shipping systems; (2) establish redundant cold chain safeguards; (3) maintain detailed drug accountability logs; (4) ensure chain-of-custody documentation; (5) train site staff; (6) audit vendors regularly; (7) adopt digital monitoring tools; (8) plan contingency stocks; (9) align labeling with FDA and state requirements; and (10) maintain inspection-ready supply records.

Click to read the full article.

Clinical Trials in USA, Country-Specific Clinical Trials